head and neck squamous cell carcinoma

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.